Reacción psoriasiforme por nivolumab: reconociendo el espectro cutáneo de la inmunoterapia

• William López-Quintero ^[1] ; María del Mar Serna-Posada ^[2] ; María Janeth Vargas-Manrique ^[1] ; Leonardo Pulido-Prieto ^[1]
  1. [1] Universidad Militar Nueva Granada

     Universidad Militar Nueva Granada

     Colombia

     
  2. [2] Universidad CES

     Universidad CES

     Colombia

     
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 39, Nº. 8 (Octubre), 2024, págs. 483-486
• Idioma: español
• DOI: 10.1016/j.piel.2024.02.021
• Títulos paralelos:
  • Psoriasiform reaction to nivolumab: Recognising the cutaneous spectrum of immunotherapy
• Texto completo no disponible (Saber más ...)
• Referencias bibliográficas
  • Cutroneo P, Ingrasciotta Y, Isgrò V, et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther....
  • De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and...
  • Coleman E, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective...
  • Thebeau M, Rubin K, Hofmann M, et al. Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma:...
  • Simonsen AB, Kaae J, Ellebaek E, et al. Cutaneous adverse reactions to anti–PD-1 treatment. A systematic review. J Am Acad Dermatol. 2020;83(5):1415–1424.
  • Mancano MA. Nivolumab-induced psoriasiform skin eruption. Hosp Pharm. 2015;50(11):965–968.
  • Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128.
  • Patel AB, Pacha O. Skin reactions to immune checkpoint inhibitors. Adv Exp Med Biol. 2021;1342:319–330. https://doi.org/ 10.1007/978-3-030-79308-1_11.
  • Ellis SR, Vierra AT, Millsop JW, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features....
  • Kim YE, Kim TM, Jo SJ. Histologically diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: a case...